Neurocrine Biosciences (NBIX) Tops Q2 EPS by 44c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $174.10 --0%
EPS Growth %: -4.2%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: -4.2%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.25, $0.44 better than the analyst estimate of $0.81. Revenue for the quarter came in at $452.7 million versus the consensus estimate of $446.75 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Deutsche Bank Starts Porvair PLC (PRV:LN) at Buy
- Goldman Sachs Downgrades Daihen Corp (6622:JP) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
